A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys

NCT06582485 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemia-reperfusion Injury
Kidney Transplant; Complications

Interventions

DRUG: iCM012 solution 2 mg/mL
DRUG: Placebo

Sponsor

iCoat Medical AB